

Cells used as carriers for bacteria

Field of the invention

- 5 The invention relates to cells infected with bacteria and to the use thereof for producing a pharmaceutical composition, in particular for the treatment of cancer.

Background of the invention and prior art.

10

Novel approaches to a therapy of previously incurable or inadequately curable disorders include the various possibilities for gene therapy and immunotherapy.

- 15 The intention in gene therapy is for a nucleic acid sequence which codes for a desired protein to be transported by suitable carriers into the target tissue, and to penetrate into cells therein and transduce them to express the desired protein. Numerous
20 different technological approaches to gene therapy have been developed and tested. However, viewed overall, the clinical results of this testing of the various approaches have tended to be disappointing overall and in particular for neoplastic diseases. Technical
25 problems are substantially the reason for this. Thus, the carriers of nucleic acid sequences show a target cell specificity which is too low, the number of cells which can be transduced is too low, and the strength and duration of expression of the desired protein is
30 too small for a therapeutic effect.

- One established form of immunotherapy is immunization with an antigen, which is called vaccination. After immunization with an antigen, the body produces
35 specific antibodies and/or specific cytotoxic lymphocytes which have prophylactic or therapeutic activity, for example against infectious agents. Various approaches have been attempted for some decades for the treatment by vaccination of previously

insufficiently treatable or incurable disorders. At the forefront of this is the therapy of neoplastic diseases by a tumor vaccination. The aim is to bring about through a tumor vaccine an immune response against the tumor, leading to lysis of tumor cells and eventually to elimination of all the tumor tissue. However, no breakthrough in tumor therapy has been achievable as yet with the various tumor vaccines tested to date. A substantial reason derives from the so-called immunotolerance of the tumor host for his tumor. Thus, although it is possible with a large number of immunotherapy approaches to induce relatively well a tumor-specific T-cell response, this frequently does not correlate with the tumoricidal effect (e.g. Thurner et al., J. Exp Med 190:1669-1678 (1999)). Recent findings point to various causes. These include insufficient penetration of the tumor tissue by specific T cells (Mukai et al., Cancer Research 59:5245-5249 (1999)) and/or inactivation of T cells inside the tumor (for example by TFG- β or by expression of negative regulatory markers such as B7-H1 in the tumor tissue or by stimulation of regulatory T cells having an immunosuppressant effect (Review: Bach, Nature Reviews, 3:189-198 (2003))).

Several methods are currently employed in different clinical phases for tumor vaccination and are frequently based on dendritic cells (summarized in Bancherau et al., Cell, 106:271-4 (2001)). The commonest type of immunization with dendritic cells comprises activation of the cells ex vivo, loading ("pulsing") thereof with antigen (for example purified protein, tumor cell extract or defined peptides) and subsequent administration thereof. Alternatively, methods which include fusion of cells are also used. In this case, for example, irradiated tumor cells are fused to dendritic cells by suitable methods such as an electric field and subsequently administered (Kugler et al., Nat Med 6:332-6 (2000)).

A novel method has been developed, with the aid of recombinant attenuated bacteria such as, for example, salmonellae and listeriae as carriers of selected tumor antigens, to break through this immunotolerance of the patient for his tumor (DE 102 08 653; DE 102 06 325, not yet published). The mechanism by which this immunotolerance can be broken through is not as yet understood in all its details. However, the accumulation, taking place after injection, of bacteria such as, for example, of salmonellae or listeriae in the tumor tissue, and the inflammation caused by these bacteria there, appear to play a substantial part in this. Thus, it is known that i.v. administration of salmonellae may be followed by accumulation of these bacteria in the tumor tissue. However, kinetic studies have shown that only a few bacteria can be found in the tumor tissue at early times after i.v. injection of bacteria, and these are capable of focal growth preferentially in the tumor tissue. Thus, if relatively large quantities of bacteria are observed in the tumor after i.v. injection, they are derived from relatively few precursors (Mei et al., Anticancer Res 22:3261-6 (2002)). However, this is unfavorable for therapeutic use, for example in the sense of gene therapy with salmonellae as gene carriers, because in this case the colonization of the tumor is not uniform; on the contrary, only a few foci with a high bacterial count are produced.

Tumors contain besides the actual tumor cells and the connective tissue a considerable number of leukocytes, in particular of lymphocytes (tumor-infiltrating lymphocytes; TIL) and of macrophages (tumor-associated macrophages; TAM). It is assumed that the tumor localization of leukocytes is influenced by expression products of the tumor cells, in particular by cytokines, endothelins and also by the hypoxia (Sica et al., Int Immunopharmacol, 2: 1045-1054 (2002); Grimshaw

et al., Eur J Immunol, 32:2393-2400 (2002)).

The function of the leukocytes localized in the tumor is contradictory. TAM in particular has been demonstrated to have an antitumor (antigen presentation; cytotoxicity; Funada et al., Oncol Rep, 10:309-313 (2003); Nakayama et al., AntiCancer Res 22:4291-4296); Kataki et al., J Lab Clin Med, 140:320-328 (2002)) and a tumor growth-promoting activity (secretion of growth factors; promotion of angiogenesis and of metastasis; Leek and Harris J., Mammary Gland Biol Neoplasia, 7:177-189 (2002); reduced secretion of cytotoxic cytokines such as Il-1 alpha; Il-1beta; IL-6; TNF alpha; Kataki et al., J Lab Clin Med, 140:320-328 (2002)).

Attempts have been made for some time to influence tumor growth by administering cytotoxic lymphocytes, TIL, natural killer cells, macrophages or dendritic cells. The clinical results were, however, contradictory (Faradji et al., Cancer Immunol Immunotherap, 33:319-326 (1991); Montovani et al., Immunology Today, 13:265-270 (1992); Ravaud et al., British J of Cancer, 71:331-336 (1995); Semino et al., Minerva Biotec, 11:311-317, 1999)). It was possible to show experimentally that injection of slightly activated macrophages may lead to a promotion of tumor growth, but injection of highly activated macrophages may lead to an inhibition of tumor growth (Mantovani et al., Immunology Today 13:265-270 (1992)). In this connection, administration of activated macrophages appears to favor tumor localization (Fidler, Adv Pharmacol, 30:271-326 (1974); Chokri et al., Int J Immunol, 1:79-84, (1990)). Nor has injection of leukocytes which had been transduced in vitro with a gene sequence coding for an antitumor protein as yet resulted in any breakthrough clinically in the treatment of tumors (Hege and Roberts, Current Opinion in Biotechnology, 7:629-634 (1996)). However, it was

shown during these studies that leukocytes, but also other cells, especially tumor cells, can reach the tumor tissue after i.v. injection (Shao J et al., Drug Deliv 2 (2001)), but that by far the most of the administered cells settle in normal tissues such as lung, spleen and liver (Adams J, Clin Pathol Mol Path 49:256-267 (1996)).

Technical problem of the invention.

10

The invention is based on the technical problem of producing means by means of which the target cell localization, especially tumor localization, of microorganisms comprising foreign DNA coding for active substances can be improved.

15

Perceptions and principles of the invention, and embodiments.

20 The invention is based on the perception that macrophages or dendritic cells which have been infected, i.e. loaded, with bacteria in vitro transport them after intravenous administration into the tumor tissue, that the amount of bacteria localized in the tumor after i.v. injection of macrophages loaded with bacteria in vitro was distinctly higher than after i.v. injection of a corresponding amount of free bacteria, that even infected heterologous tumor cells accumulate in tumors, and that this effect is maintained even when the infected cells have been inactivated beforehand by irradiation.

30

If, for example, macrophages were used as carriers for salmonellae, ten times more salmonellae were detectable in the tumor tissue 18 hours after i.v. administration of the macrophages loaded with salmonellae than after i.v. injection of a corresponding amount of free salmonellae in two different transgenic tumor models (lung tumor model: Raf transgenic mice, Kerkhoff et

35

al., Cell Growth Differ, 11:185-90 (2000), breast tumor model: Her-2 transgenic mice, Bouchard et al., Cell, 57:931-6 (1989)).

5 The findings were similar on use of a heterologous tumor line. The tumor cell line 4T1 (ATCC No. CRL-2539) is derived from a tumor of mammary gland tissue of BALB/c mice and was administered, after infection with attenuated listeriae, in the Raf tumor model described
10 (C57BL/6 background). The finding in this case on use of infected cells was also of a greatly increased number of bacteria in the tumor tissue, which was maintained even on previous irradiation of the cells.

15 It is thus possible in principle to extend these surprising observations to any cells as long as these cells can be infected by bacteria or onto which bacteria adhere firmly, and thus are carriers of these bacteria. Thus, for example in the abovementioned tumor
20 models, it was found that the localization of salmonellae in the tumor tissue was far greater after i.v. injection of tumor cells infected with salmonellae than after i.v. injection of a corresponding amount of free salmonellae.

25 Bacteria have a strong adjuvant effect in particular through bacterial constituents such as lipopolysaccharides (LPS), cell wall constituents, flagella, bacterial DNA having immunostimulatory CpG
30 motifs, all of which interact with various so-called Toll-like receptors (TLR) on antigen-presenting cells and are thus able to stimulate them. It is therefore to be expected that infection of cells with bacteria and administration of these cells not only brings about an
35 improved accumulation of the bacteria in the tumor, but that this infection will also result in an inflammation and a strengthening of the systemic and local immune response. This method can thus also be employed for increasing the local immune response as part of an

immunotherapy.

The invention thus relates to mammalian cells which are loaded with bacteria for the prophylaxis or therapy of a disorder, where the cell is autologous, 5 allogeneic or xenogeneic and is selected from the group consisting of macrophages, dendritic cells, granulocytes, lymphocytes, tumor cells and tissue cells, wherein the bacteria harbor recombinant DNA, the DNA coding for at 10 least one active substance. The invention also relates to these cells for use in the prevention or treatment of a disorder.

Cells in the context of this invention may be for example 15 autologous, allogeneic or xenogenic macrophages, lymphocytes, dendritic cells or tumor cells. When tumor cells are used they are preferably irradiated or treated with a cytostatic in such a way that their ability to divide is blocked. Such cells are preferably isolated 20 from the blood or from tumors by methods known to the skilled worker. However, it is also possible to use autologous, allogeneic or xenogeneic cells established in culture, called cell lines from normal tissues or from tumors. Such cell lines are obtainable in any type and 25 number for example from cell libraries such as the American tissue cell library (ATCC). It is also furthermore possible to use cells which have been modified by methods known to the skilled worker. Modifications here include in particular genetic 30 modifications, but also additional loading of the cells such as, for example, with peptides, proteins, pharmacological active substances or viral particles.

Loading in the context of the invention is the absorption 35 of bacteria onto the cell, phagocytosis of the bacteria by the cell and/or infection of the cell.

Bacteria in the context of the invention are, for example, Gram-negative and Gram-positive bacteria, preferably optionally intracellular bacteria, preferably salmonellae or listeriae, preferably bacteria which are able to divide but have no pathogenicity for the recipient or whose virulence is attenuated or which are killed. Bacteria whose virulence is attenuated are characterized for example

in that in at least one chromosome of these bacteria at least one gene for a metabolic enzyme is deleted or mutated so that the metabolic enzyme is defective. In these bacteria it is possible for i) one gene for an enzyme for synthesizing aromatic amino acids to be deleted in the chromosome, for example the *aroA* gene which codes for the first enzyme in the biosynthesis of aromatic amino acids, so that these bacteria depend for their growth on the presence of aromatic amino acids, ii) the proteins which make the motility of the bacteria possible to be expressed unimpaired, for example for the ability of the *iap* and *actA* genes to function to be retained, and iii) the gene *trpS* coding for the tryptophanyl-tRNA synthetase to be deleted in the chromosome, there having been introduction into these bacteria of plasmids, iv) whose replication has been stabilized by a suitable replication origin, for example by *ori pAM β 1* (Simon and Chopin, 1988), v) which comprise the *trpS* gene coding for tryptophanyl-tRNA synthetase, vi) which comprise a gene for an endolysin, for example the lysis gene of the phage A118 (*ply 118*; Loessner et al., 1995) under the control of a promoter which can be activated in the cytosol of mammalian cells, for example the *actA* promoter (*PactA*, Dietrich et al., 1998), and vii) which comprise at least one nucleotide sequence coding for at least one active substance under the control of a promoter which can be activated in bacteria or in mammalian cells, it being possible for the activation of the promoter to be non-cell-specific, cell-specific, cell cycle-specific, cell function-specific or dependent on metabolites, medicaments or on the oxygen concentration.

Bacteria of this type exhibit, owing to the loss of at least one gene for an essential metabolic protein, a drastic reduction in their virulence, for example measured by their ability to multiply *in vivo*, and nevertheless show a considerably increased bactofection, a lysis of the bacteria in the cytosol, a

release of the plasmids contained in the bacteria, and a stable expression of the active substance encoded by the plasmid. Such a bacterial microorganism very generally comprises a foreign nucleic acid sequence which codes for an active substance and is optionally under the control of a regulatory nucleic acid sequence, where in the chromosomal DNA of the microorganism a natural nucleic acid sequence of the bacterium which codes for the expression of a bacterial enzyme is either deleted or mutated with the proviso that a translation product derived therefrom is non-functional, and where the microorganism comprises no foreign nucleic acid sequence which codes for the enzyme.

Examples of intracellular bacteria are: *Mycobacterium tuberculosis*, *M. bovis*, *M. bovis* strain BCG, BCG substrains, *M. avium*, *M. intracellulare*, *M. africanum*, *M. kansasii*, *M. marinum*, *M. ulcerans*, *M. avium* subspecies *paratuberculosis*, *Nocardia asteroides*, other *Nocardia* species, *Legionella pneumophila*, other *Legionella* species, *Salmonella typhi*, *S. typhimurium*, other *Salmonella* species, *Shigella* species, *Yersinia pestis*, *Pasteurella haemolytica*, *Pasteurella multocida*, other *Pasteurella* species, *Actinobacillus pleuropneumoniae*, *Listeria monocytogenes*, *L. ivanovii*, *Brucella abortus*, other *Brucella* species, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Chlamydia psittaci* and *Coxiella burnetii*.

Examples of attenuations of salmonellae are: inactivating mutations in a *pab* gene, a *pur* gene, an *aro* gene, *asd*, a *dap* gene, in *nadA*, *pncB*, *galE*, *pmi*, *fur*, *rpsL*, *ompR*, *htrA*, *hemA*, *cdt*, *cya*, *crp*, *dam*, *phoP*, *phoQ*, *rfc*, *poxA*, *galU*, *metL*, *metH*, *mviA*, *sodC*, *recA*, *ssrA*, *ssrB*, *sirA*, *sirB*, *sirC*, *inv*, *hliA*, *hliC*, *hliD*, *rpoE*, *flgM*, *tonB* or *slyA*, and combinations thereof. The inactivating mutations of the genes which are listed by way of example for attenuation of salmonellae are

familiar to the skilled worker.

Nucleic acid sequences have been introduced into bacteria which are carried by the cells of the invention. The

5

nucleic acid sequences code for a protein, these proteins preferably representing active substances for the prevention or treatment of a disorder.

10

Such proteins may be for example: antigens of infectious agents such as viruses, bacteria, mycoplasmas, parasites, antigens specific for tumors, in particular proteins encoded by oncogenes, antibodies, epitope-binding fragments of antibodies and fusion proteins comprising at least one epitope-binding fragment of an antibody directed for example against an antigen on a tumor cell, on a lymphocyte such as, for example, a T lymphocyte or on an endothelial cell such as, for example, a tumor endothelial cell, enzymes, in particular enzymes for activating inactive precursors of a medicament such as, for example, a β -glucuronidase, a phosphatase, a hydrolase, a lipase, immunosuppressant cytokines such as, for example, IL-10, immunostimulating cytokines such as, for example, IL-1, IL-2, IL-3 or IL-6, chemokines, interferons, growth factors such as, for example, G-CSF, GM-CSF, M-CSF, FGF; VEGF or EGF, or inhibitory proteins for cytokines, chemokines, interferons or growth factors.

25

The expression of these genes in the bacteria is regulated by suitable promoters, it being possible for these to derive from the bacteria or from viruses or from eukaryotes and to be nonspecifically, cell-specifically or function-specifically activatable.

35

In a further preferred embodiment of the invention, nucleic acid sequences which enable transmembrane expression or secretion of the gene-encoded protein by

the bacterium are attached to the gene. Examples of such so-called signal sequences are described in the references EP 1042495, EP 1015023 and Hess et al., PNAS USA 93:1458-1463 (1996).

5

The invention further relates to a cell of the invention for use in the prevention or treatment of a disorder. The cells of the invention are preferably used for treating a neoplastic disease or an immune disease.

10 For this purpose, the gene introduced into the bacteria encodes a protein which i) is tumor-cytolytic, ii) has proinflammatory effects, iii) inhibits negatively regulating immune cells, such as, for example, through inhibition of CTLA-4, of B7-H1 or of CD25 or of TGF β , iv)
15 has immunosuppressant effects or v) can convert an inactive precursor of a cytotoxic, immunomodulating or immunosuppressant substance into an active substance.

For the prevention or treatment of a disorder, preferably
20 from 100 to 10⁹ cells which preferably carry about 0.1 (statistical mean) to 100 bacteria per cell are administered. Such cells are administered locally on the skin, into the circulation, into a body cavity, into a tissue, into an organ or orally, rectally or bronchially
25 at least once.

Disorders for which the cells of the invention are used are, for example, neoplastic diseases, autoimmune diseases, chronic inflammations and organ transplants.

30

The invention also relates to the use of cells of the invention for the manufacture of a medicament for the prophylaxis or therapy of a disorder selected from neoplastic diseases, autoimmune diseases, chronic
35 inflammations and organ transplants.

The invention is explained in more detail below by means of exemplary embodiments.

Examples to illustrate the invention

- 5 Example 1: Provision of Salmonella typhimurium 7207 by
infected autologous bone marrow macrophages

1.1: Isolation of bone marrow macrophages (MΦ).

BxB23 mice about 2-3 months old, or MMTV/neu transgenic mice about 2 months old were used to isolate bone marrow macrophages. The macrophages were isolated according to the following protocol: i) remove the femur from the mouse, ii) remove soft tissues from bone in a Petri dish and cut open bilaterally, iii) rinse bone marrow with 2 ml of DMEM 10 (DMEM Gibco with 10% FCS Gibco, 2 mM L-glutamine Gibco, 50 μM β-mercaptoethanol Gibco) with the aid of a syringe in Bluecap with DMEM 10, iv) centrifugation at 1200 rpm for 5', aspirate and take up in 5 ml of differentiation medium. Adjust to a cell count of 1×10^5 cells/ml in differentiation medium (DMEM 10 + 10 ng/ml GM-CSF (recombinant mouse granulocyte macrophage colony stimulating factor; RD Systems, Wiesbaden Cat. No.: 415-ML) and distribute in 5 ml portions in Nunc culture dishes (NUNCTM, 58 mm, NUNC No.: 16955), v) incubate at 37°C and 10% CO₂ for 8 days, vi)

1.2: Infection of macrophages with *Salmonella typhimurium* 7207 (SL7207) in vitro.

The MΦ adhering to the NUNC cell culture dish were washed with DMEM and then the adherent cells were harvested with a cell scraper, counted and taken up in differentiation medium. Infection with SL7207 (Hoiseth S.K. et al., Nature 291:238-239 (1981)) took place according to the following protocol: i) 37°C, 1 h in an incubator: MOI (multiplicity of infection) 1:20, ii) 10^6 macrophages were seeded in 2 ml of medium in a NUNC culture dish and incubated with 2×10^7 bacteria (MOI = 20) at 37°C for 1 h, iii) then wash, iv) incubate with gentamycin (final conc. 100 μg/ml (Sigma)) 1 h, 37°C, v) wash, determine cell count, plate out on brain heart infusion (BHI) plates (Gibco) for counting the bacterial colony-forming units (CFUs).

1.3: Results of the loading of macrophages.

With an MOI of 20 and a loading time of one hour it is

possible constantly to detect about 10^4 salmonellae in 10^5 macrophages. The loading density remained approximately constant for 12 hours after the loading and shows no bacterial proliferation at all.

5

1.4: Administration of macrophages infected "in vitro" with SL 7207 in BxB23 and MMTV/neu tumor mice

5x15⁵ bone marrow macrophages infected in vitro and suspended in 100 µl of PBS were injected i.v. and per
10 mouse into the tail vein of BxB23 and MMTV/neu tumor mice (the experimental animals used showed advanced tumor development, age about 12 months, the lung mass due to the lung tumors in the BxB23 mice amounted to 0.75-1.25 g). Depending on the experiment, a bacterial
15 count of $3-5 \times 10^4$ S. typhimurium 7207 was injected (determined by counting the CFUs) per mouse. As control, S. typhimurium 7207 was administered i.v. (2.5×10^5 bacteria suspended in 100 µl of PBS per mouse) to BxB23 and MMTV/neu tumor mice. After 18 h,
20 the animals were sacrificed and the CFU (plated out on BHI plates) in the lung (BxB23) and in the tumor (MMTV) were determined. The progress of the infection was investigated in the control group after i.v. injection of S. typhimurium aroA 7207. For this purpose, the
25 bacterial count was investigated by determining the CFUs at various times using the same protocol.

1.5: Accumulation of S. typhimurium 7207 in tumors after i.v. injection:

30 The amount of salmonellae detected in the tumor-bearing lungs of BxB23 mice and in mammary tumors of MMTV/neu mice after administration of salmonellae-infected macrophages was more than ten times that in animals in the control group, which had been treated with free
35 salmonellae, 18 hours after the infection. Following injection of bacteria-loaded macrophages, the accumulation of the bacteria even 18 hours after the injection was as high (factor 10 higher than on injection of naked bacteria, see fig. 1 and relevant

table) as could be achieved comparatively in the control group (i.e. after injection of the bacteria alone) only after some days (day 5 after infection). It was accordingly possible with the aid of the bacteria-loaded cells of the invention to accumulate a distinctly larger number of bacteria in a substantially shorter time in the tumor than was possible after injection of the pure bacterial suspension. Determination of the CFUs in the lungs and the organs on days 1, 7, 14 after injection of the cells of the invention revealed that the CFUs remained at a constant high level or increased in the lungs of the tumor-bearing BxB23 mice, whereas the CFUs in the lungs of the C57BL/6 control mice and in the spleens of the BXB23 mice and of the C57BL/6 mice fell distinctly below the values in the respective lungs or were no longer detectable (see fig. 2 and fig. 3, and relevant tables; fig. 2 shows a comparison of the CFUs in lungs of (lung) tumor-bearing BxB23 mice with lungs of the C57BL/6 control animals, fig. 3 a comparison of the CFUs in the mammary tumors and in the spleen of MMTV/neu mice after i.v. injection of 5×10^5 *S. typhimurium*).

Example 2: Provision of *L. monocytogenes* by infected heterologous cells

4T1 cells (ATCC CRL-2539) of a tumor line from a mammary gland tumor of BALB/c mice were infected with the attenuated *L. monocytogenes* strain and an MOI of 10 over a period of 1 h. The cells were then washed, and free bacteria were killed by incubation in the presence of gentamycin for one hour. Determination of the CFUs revealed a loading of the cells with 0.15 bacteria per cell. The cell count was adjusted to 5×10^6 cells per ml in PBS. In addition, some of the infected cells were inactivated by irradiation. 0.1 ml of this suspension [i.e. 5×10^5 infected cells (measured CFU of listeriae: 7.3×10^4), 3.5×10^5 infected and irradiated cells or

(counted CFUs) 3.5×10^5 free listeriae, each in 100 μ l of PBS] per mouse were injected i.v. into tumor-bearing BxB23 mice (age > 10 months) or C57BL/6 mice of the same age.

5 With the radiation dose used there is a reduction, detected by CFU determination, in free bacteria by a maximum of 25%, resulting in a calculated infectious dose of about 3.8×10^4 bacteria in the case of irradiated cells.

10

17 h after the infection, the bacterial CFUs were determined in the lung and spleen by serial plating on BHI plates (Gibco) (limit of detection 10 bacteria per organ).

15

All animals showed a successful infection according to the detectable CFUs in the spleen. The number of CFUs after injection of the living or irradiated cells of the invention was distinctly higher in the lungs of the tumor-bearing BxB23 mice and of the C57BL/6 control mice than after injection of the bacterial suspension, and the bacterial count after injection of the cells of the invention was distinctly increased in the lungs of the tumor-bearing BxB23 mice compared with the bacterial count in the lungs of the C57BL/6 control mice (factor 10). Considerably more bacterial CFUs were detectable in the spleen of all groups than in the lung, but it was not possible to detect a clear difference in the number of bacterial CFUs after injection of the cells of the invention or of the bacterial suspension both in tumor-bearing BxB23 mice and in the C57BL/6 control mice (see fig. 4 and the relevant table).

35 As already demonstrated in the abovementioned control groups in the experiments with macrophages loaded with virulence-attenuated *S. typhimurium* 7207, in the case of virulence-attenuated *L. monocytogenes* too there is a reduction in the number of the bacterial CFUs in the

spleen and in other, nontumor-bearing organs within a period of about 5 days, but a maximum of 14 days after injection both of the cells of the invention and of the pure bacterial suspension, both in the tumor-bearing
5 BxB23 mice and in C57BL/6 control mice to levels which are distinctly below the levels of the CFUs in the lungs of the (lung) tumor-bearing BxB23.

In contrast thereto, the initially increased number of
10 bacterial CFUs in the lungs of the (lung) tumor-bearing BxB23 mice at least persists after injection of the cells of the invention over the entire period or even increases initially, only to fall again after a prolonged plateau phase.

Table 1: Bacterial count in lungs or tumors of infected mice 18 hours after i.v. injection of infected macrophages or free salmonellae.

Mouse line	S.T. + macrophages			S. typhimurium		
	CFU	SEM	n	CFU	SEM	n
BxB23 (lung)	9.000	3.600	3	0	0	2
MMTV Her (tumor)	5.850	1.552	4	66	66	2

5

Table 2: Comparison of the CFUs in lungs of (lung) tumor-bearing BxB23 mice with lungs with the C57BL/6 control animals

Day	BxB23			WT C57/B16		
	CFU	SEM	n	CFU	SEM	n
2	1.485	1.335	2			
3	1.255	229	7	700	600	2
4	910	210	2			
5	2.469	1.503	6			
7	4.499	1.694	6	500	400	2
14	2.900	1.700	2	750	250	2
18	2.225	975	2			

10

Table 3: Comparison of the CFUs in the mammary tumors and in the spleen of MMTV/neu mice after i.v. injection of 5×10^5 S. typhimurium aroA

Day	Tumor			Spleen		
	Log (CFU)	SEM	n	Log (CFU)	SEM	n
3	2.67	0.24	2	4.65	0.10	2
4	3.19	0.68	4			
18	3.20	0.20	2	2.14	0.06	2

15

Table 4: Bacterial count in infected mice 17 hours after infection with infected 4T1 breast tumor cells with (irrad. cells) or without (inf. cells) irradiation with 25 gray or free listeriae.

5

	BxB23			C57BL/6	
	Inf. cells	Inf. irradiated cells	L. mon. aroA	Inf. cells	L. mon. aroA
Log (CFU)	3.572	2.437	0.6344	2.601	0.4337
SEM	0.133	0.5261	0.6344	0.01688	0.4337
n	3	3	3	3	3

Table 5: Bacterial count in the spleen of infected mice 17 hours after infection with infected 4T1 breast tumor cells with (irrad. cells) or without (inf. cells) irradiation with 25 gray or free listeriae.

10

	BxB23			C57BL/6	
	Inf. cells	Inf. irradiated cells	L. mon. aroA	Inf. cells	L. mon. aroA
Log (CFU)	5.224	2.934	4.045	4.37	4.57
SEM	0.1596	0.4338	0.9131	0.3023	0.2573
n	3	3	3	3	3

Claims:

- 1.) A mammalian cell which is loaded with bacteria for the prophylaxis or therapy of a disorder, where the cell is autologous, allogeneic or xenogeneic and is selected from the group consisting of "macrophages, dendritic cells, granulocytes, lymphocytes, tumor cells and tissue cells, wherein the bacteria harbor recombinant DNA, the DNA coding for at least one active substance".
- 2.) The cell as claimed in claim 1, which is inactivated by irradiation or other methods.
- 3.) The cell as claimed in claim 1 or 2, where the bacteria are alive, nonvirulent, virulence-attenuated or dead.
- 4.) The cell as claimed in any of claims 1 to 3, where the bacteria are selected from the group consisting of "Mycobacterium tuberculosis, M. bovis, M. bovis strain BCG, BCG substrains, M. avium, M. intracellulare, M. africanum, M. kansasii, M. marinum, M. ulcerans, M. avium subspecies paratuberculosis, Nocardia asteroides, other Nocardia species, Legionella pneumophila, other Legionella species, Salmonella typhi, S. typhimurium, other Salmonella species, Shigella species, Yersinia pestis, Pasteurella haemolytica, Pasteurella multocida, other Pasteurella species, Actinobacillus pleuropneumoniae, Listeria monocytogenes, L. ivanovii, Brucella abortus, other Brucella species, Chlamydia pneumoniae, Chlamydia trachomatis, Chlamydia psittaci and Coxiella burnetii".

- 5.) The cell as claimed in any of claims 1 to 4, where
5 at least one active substance is produced by the
bacteria themselves with the aid of suitable
promoters, or expression thereof is under the
control of a eukaryotic promoter.
- 6.) The cell as claimed in any of claims 1 to 5, where
10 intracellular, membrane-associated or secretory
production takes place.
- 7.) The cell as claimed in any of claims 1 to 6, in
15 which the active substance is selected from the
group consisting of "antigens of infectious agents
such as viruses, bacteria, mycoplasmas, parasites,
antigens specific for tumors, in particular proteins
encoded by oncogenes, antibodies, epitope-binding
20 fragments of antibodies and fusion proteins
comprising at least one epitope-binding fragment of
an antibody directed for example against an antigen
on a tumor cell, on a lymphocyte such as, for
example, a T lymphocyte or on an endothelial cell
such as, for example, a tumor endothelial cell,
25 enzymes, in particular enzymes for activating
inactive precursors of a medicament such as, for
example, a β -glucuronidase, a phosphatase, a
hydrolase, a lipase, immunosuppressant cytokines
such as, for example, IL-10, immunostimulating
30 cytokines such as, for example, IL-1, IL-2, IL-3 or
IL-6, chemokines, interferons, growth factors such
as, for example, G-CSF, GM-CSF, M-CSF, FGF; VEGF or
EGF, or inhibitory proteins for cytokines,
chemokines, interferons or growth factors".
- 8.) The use of a cell as claimed in any of claims 1 to 7
35 for the manufacture of a medicament for the
prophylaxis or therapy of a disorder selected from

neoplastic diseases, autoimmune diseases, chronic inflammations and organ transplants.

- 5 9.) The use of a cell as claimed in any of claims 1 to
7 for the manufacture of a medicament for the
prophylaxis or therapy of a disorder selected from
neoplastic diseases, autoimmune diseases, chronic
inflammations and organ transplants, where the
active substance blocks negative regulatory elements
10 in the tumor tissue.
- 15 10.) The use of a cell as claimed in any of claims 1 to
7 for the manufacture of a medicament for the
prophylaxis or therapy of a disorder selected from
neoplastic diseases, autoimmune diseases, chronic
inflammations and organ transplants, where the
bacteria serve as proinflammatory stimulant in tumor
tissue.
- 20 11.) The use of a cell as claimed in any of claims 1 to
7 for the manufacture of a medicament for the
prophylaxis or therapy of a disorder selected from
neoplastic diseases, autoimmune diseases, chronic
inflammations and organ transplants, where dendritic
25 cells or macrophages are employed simultaneously as
carrier for a vaccine antigen.
- 30 12.) The use of a cell as claimed in any of claims 1 to
7 for the manufacture of a medicament for the
prophylaxis or therapy of a disorder selected from
neoplastic diseases, autoimmune diseases, chronic
inflammations and organ transplants, where the
active substance and/or the vaccine antigen is
loaded ex vivo onto the dendritic cells or onto the
35 macrophages.
- 13.) The use as claimed in claim 12 , where the vaccine
antigen consists of defined peptides.

- 14.) The use as claimed in claim 10 , where the cell is fused to another cell which expresses a tissue antigen or a tumor antigen.
- 5
- 15.) The use as claimed in claim 14, where the fused cells are autologous tumor cells.
- 10
- 16.) The cells as claimed in any of claims 1 to 7 for use in the prophylaxis or therapy of a disorder.
- 15
- 17.) The use of a cell, in particular as claimed in any of claims 1 to 7, which is loaded with a microorganism comprising a foreign DNA, in particular bacterial microorganism, for the preparation of a pharmaceutical composition.
- 20
- 18.) The use as claimed in claim 17, where the foreign DNA codes for a defined active substance, and where the pharmaceutical composition is intended for the prophylaxis or treatment of a disorder which can be prevented and/or treated with the active substance.